文献速递生殖医学

滋肾育胎丸对比安慰剂对新鲜胚胎移植周期女性活产率的影响:一项随机对照试验

Effects of the Zishen Yutai Pill Compared With Placebo on Live Births Among Women in a Fresh Embryo Transfer Cycle: A Randomized Controlled Trial.
PubMed 文献 · Obstet Gynecol · 2022-01-01

这项双盲、多中心、安慰剂对照随机试验纳入2265例新鲜胚胎移植女性,评估滋肾育胎丸对活产率的影响。意向性分析显示,滋肾育胎丸组活产率为26.8%,安慰剂组为23.0%(RR 1.16,95%CI 1.01-1.34,P=.038),着床率、生化妊娠率和临床妊娠率也均高于安慰剂组。两组妊娠丢失率及母儿并发症无显著差异(均P>.05)。

要点

  • 滋肾育胎丸组活产率26.8%,安慰剂组23.0%(RR 1.16,95%CI 1.01-1.34,P=.038)。
  • 着床率36.8% vs 32.6%(RR 1.13,95%CI 1.01-1.25,P=.027)。
  • 妊娠丢失率及母儿并发症两组无显著差异(均P>.05)。

核心结论

  • 与安慰剂相比,滋肾育胎丸提高了新鲜胚胎移植后的活产率。

研究设计与样本

  • 双盲、多中心、安慰剂对照随机试验,筛查2580例,随机2265例,滋肾育胎丸组1131例、安慰剂组1134例,按1:1分组。
  • 研究对象为体外受精或卵胞浆内单精子注射后行新鲜胚胎移植的女性。
  • 干预为口服滋肾育胎丸5 g或安慰剂,每日三次。

主要发现

  • 意向性分析活产率:滋肾育胎丸组26.8% vs 安慰剂组23.0%(RR 1.16,95%CI 1.01-1.34,P=.038)。
  • 着床率:滋肾育胎丸组36.8% vs 安慰剂组32.6%(RR 1.13,95%CI 1.01-1.25,P=.027)。
  • 生化妊娠率:滋肾育胎丸组35.5% vs 安慰剂组31.1%(RR 1.14,95%CI 1.02-1.28,P=.026)。
  • 临床妊娠率:滋肾育胎丸组31.2% vs 安慰剂组27.3%(RR 1.14,95%CI 1.00-1.30,P=.043)。
  • 妊娠丢失率、母体并发症及新生儿并发症两组均无显著差异(均P>.05)。

关键数值与推荐

  • 主要结局为活产率,次要结局包括着床率、生化妊娠率、临床妊娠率、妊娠丢失率、周期取消率及母体、胎儿和新生儿并发症。
  • 样本量2265例用于检测滋肾育胎丸与安慰剂间活产率差异。

临床怎么用

  • 作者结论认为滋肾育胎丸较安慰剂提高了新鲜胚胎移植后的活产率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy of the Zishen Yutai Pill compared with placebo on live birth rates among women after fresh embryo transfer cycles. METHODS: We conducted a double-blind, multicenter, placebo-controlled, randomized trial to investigate whether administration of the Zishen Yutai Pill would improve pregnancy outcomes among women undergoing fresh embryo transfer after in vitro fertilization or intracytoplasmic sperm injection. The primary outcome was live birth rate. Secondary outcomes were rates of implantation, biochemical pregnancy, clinical pregnancy, pregnancy loss, cycle cancellation, and maternal, fetal, and neonatal complications. A total sample size of 2,265 women (1:1 in two groups) was used to detect a live birth rate difference between the Zishen Yutai Pill and placebo. Participants were enrolled and randomized to receive 5 g of the Zishen Yutai Pill or placebo orally, three times per day during the study. RESULTS: Recruitment was completed between April 2014 and June 2017, with 2,580 patients screened. Two thousand two hundred sixty-five patients were randomized: 1,131 to the Zishen Yutai Pill and 1,134 to placebo. Characteristics were similar between groups. In intention-to-treat analysis, the rates of live birth in the Zishen Yutai Pill (ZYP) group and placebo group were 26.8% and 23.0% (rate ratio [RR], 1.16; 95% CI 1.01-1.34; P=.038), respectively. The implantation rates were 36.8% and 32.6% in the ZYP and placebo groups, respectively (RR 1.13; 95% CI 1.01-1.25; P=.027). The biochemical pregnancy rate for the ZYP group was 35.5% compared with 31.1% in the placebo group (RR 1.14; 95% CI 1.02-1.28; P=.026). The rates of clinical pregnancy in the ZYP and placebo groups were 31.2% compared with 27.3%, respectively (RR 1.14; 95% CI 1.00-1.30; P=.043). There were no significant between-group differences in the rates of pregnancy loss, maternal, or neonatal complications (all P>.05). CONCLUSION: The Zishen Yutai Pill increased the rate of live birth after fresh embryo transfer compared with placebo. CLINICAL TRIAL REGISTRATION: Chictr.org.cn, Chictr-TRC-14004494.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Chen X, Hao C, Deng W, et al. Effects of the Zishen Yutai Pill Compared With Placebo on Live Births Among Women in a Fresh Embryo Transfer Cycle: A Randomized Controlled Trial. Obstet Gynecol. 2022. PMID: 34991130. doi:10.1097/AOG.0000000000004658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。